News on molecular diagnostics, pharmacogenomics tests for coronary artery disease, congenital heart defects, and more.
An Australian team developed a decision model for testing asymptomatic relatives of patients with dilated cardiomyopathy to assess the cost effectiveness of testing.
The mass spec-based panel using 26 protein biomarkers is being developed to detect heart failure earlier than with existing BNP-only-based tests.
Akonni has received clearance for a molecular diagnostic instrument and a saliva-based pharmacogenomics test for warfarin metabolism.
The guidelines provide recommendations for what CYP2C9 variant alleles should be included in clinical pharmacogenomic tests assessing that gene.
The researchers said such a screening approach could capture younger individuals who don't regularly visit medical professionals.
